Mechanism of the immunosuppressive effect in vivo of novel immunosuppressive drug β-SQAG9, which inhibits the response of the CD62L+ T-cell subset

Five of 11 (45.5%) rats that were treated with 50 mg/kg β-SQAG9 liposome showed graft survival and another showed moderate rejection in graft. The CD62L+ T-cell subset population in ALNs of β-SQAG9 liposome-treated rats decreased in a dose-dependent manner. No significant difference in the T-cell population was observed between the β-SQAG9 and control groups. These data suggest that β-SQAG9 could bind to the CD62L+ T-cell subset in vivo as well as in vitro and affect T-cell migration, which might lead to T-cell tolerance in vivo.